Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia

Haematologica

Volumn 90, Issue 8, 2005, Pages 1116-1127

  De Keersmaecker, Kim ^a   Marynen, Peter ^a   Cools, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b Campus Gasthuisberg O and N 06 ^*  (Belgium)

Author keywords

Differentiation; Oncogene; Proliferation; Self renewal; Stem cell; Survival; Transcription factor; Tumor suppressor gene; Tyrosine kinase

Indexed keywords

ABELSON KINASE; CYCLIN DEPENDENT KINASE; FLT3 LIGAND; GAMMA SECRETASE; HELIX LOOP HELIX PROTEIN; HOX PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE; RAS PROTEIN; T LYMPHOCYTE RECEPTOR; TLX1 PROTEIN; TLX3 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; GENETIC TRANSCRIPTION; HOMEOBOX; HUMAN; HUMAN CELL; LEUKEMOGENESIS; ONCOGENE; PATHOGENESIS; REVIEW; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE;

HELIX-LOOP-HELIX MOTIFS; HUMANS; LEUKEMIA, T-CELL, ACUTE; NEOPLASM PROTEINS;

EID: 24944489213     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Croce CM, Isobe M, Palumbo A, Puck J, Ming J, Tweardy D, et al. Gene for a-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science 1985;227:1044-7.
2. Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G, Flake T, et al. New chromosomal translocations correlate with specific immunophenotypes of childhood acute lympnoblastic leukemia. Cell 1984;36:101-9.
3. Raimondi SC, Behm FG, Roberson PK, Pui CH, Rivera GK, Murphy SB, et al. Cytogenetics of childhood T-cell leukemia. Blood 1988;72:1560-6.
4. Schneider NR, Carroll AJ, Shuster JJ, Pullen DJ, Link MP, Borowitz MJ, et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. Blood 2000;96:2543-9.
5. Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, et al. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998;16:1270-8.
6. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36:1084-9.
7. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
8. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;3:179-98.
9. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8:189-91.
10. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
11. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994;84:4038-44.
12. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2003;37:44-57.
13. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 1998;23:291-6.
14. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
15. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-9.
16. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
17. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722-7.
18. Jagasia AA, Sher DA, Le Moine PJ, Kim DH, Moldwin RL, Smith SD, et al. Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells. Leukemia 1996;10:624-8.
19. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, et al. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res 2000;6:1219-28.
20. Owens BM, Hawley RG. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells 2002;20:364-79.
21. Magli MC, Barba P, Celetti A, De VG, Cillo C, Boncinelli E. Coordinate regulation of HOX genes in human hematopoietic cells. Proc Natl Acad Sci USA 1991;88:6348-52.
22. van OJ, Bijl J, Raaphorst F, Walboomers J, Meijer C. The role of homeobox fenes in normal hematopoiesis and hematological malignancies. Leukemia 1999;13:1675-90.
23. Lawrence HJ, Largman C. Homeobox genes in normal hematopoiesis and leukemia. Blood 1992;80:2445-53.
24. Buske C, Humphries RK. Homeobox genes in leukemogenesis. Int J Hematol 2000;71:301-8.
25. Roberts CW, Shutter JR, Korsmeyer SJ. Hox11 controls the genesis of the spleen. Nature 1994;368:747-9.
26. Dear TN, Colledge WH, Carlton MB, Lavenir I, Larson T, Smith AJ, et al. The Hox11 gene is essential for cell survival during spleen development. Development 1995;121:2909-15.
27. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2004;103:442-50.
28. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75-87.
29. Hatano M, Roberts CW, Minden M, Grist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 1991;253:79-82.
30. Lu M, Gong ZY, Shen WF, Ho AD. The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein. EMBO J 1991;10:2905-10.
31. Dube ID, Kamel-Reid S, Yuan CC, Lu M, Wu X, Corpus G, et al. A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood 1991;78:2996-3003.
32. Kennedy MA, Gonzalez-Sarmiento R, Kees UR, Lampert F, Dear N, Boehm T, et al. HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proc Natl Acad Sci USA 1991;88:8900-4.
33. Salvati PD, Ranford PR, Ford J, Kees UR. HOX11 expression in pediatric acute lymphoblastic leukemia is associated with T-cell phenotype. Oncogene 1995;11:1333-8.
34. Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox EA, et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood 2004;103:1909-11.
35. Watt PM, Kumar R, Kees UR. Promoter demethylation accompanies reactivation of the HOX11 protooncogene in leukemia. Genes Chromosomes Cancer 2000;29:371-7.
36. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004;363:535-6.
37. Hawley RG, Fong AZ, Lu M, Hawley TS. The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene 1994;9:1-12.
38. Hawley RG, Fong AZ, Reis MD, Zhang N, Lu M, Hawley TS. Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res 1997;57:337-45.
39. Hoffmann K, Dixon DN, Greene WK, Ford J, Taplin R, Kees UR. A microarray model system identifies potential new target genes of the proto-oncogene HOX11. Genes Chromosomes Cancer 2004;41:309-20.
40. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002;100:991-7.
41. Berger R, Dastugue N, Busson M, van den AJ, Perot C, Ballerini P, et al. t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 2003;17:1851-7.
42. Bernard OA, Busson-LeConiat M, Ballerina P, Mauchauffe M, Della V, V, Monni R, et al. A new recurrent and specific cryptic translocation, t(5;14) (q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001;15:1495-504.
43. van Zutven LJ, Velthuizen SC, Wolvers-Tettero IL, van Dongen JJ, Poulsen TS, MacLeod RA, et al. Two dual-color split signal fluorescence in situ hybridization assays to detect t(5;14) involving HOX11L2 or CSX in T-cell acute lymphoblastic leukemia. Haematologica 2004;89:671-8.
44. Nagel S, Kaufmann M, Drexler HG, Macleod RA. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14) (q35.1;q32.2). Cancer Res 2003;63:5329-34.
45. Su XY, Busson M, Della V, V, Ballerini P, Dastugue N, Talmant P, et al. Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2004;41:243-9.
46. Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, Poppe B, et al. A new recurrent inversion, inv(7) (p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 2005;19:358-66.
47. Taghon T, Thys K, De SM, Weerkamp F, Staal FJ, Plum J, et al. Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development. Leukemia 2003;17:1157-63.
48. Taghon T, Stolz F, De SM, Cnockaert M, Verhasselt B, Plum J, et al. HOXA10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific transcription factor. Blood 2002;99:1197-204.
49. Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE, Eaves CJ, et al. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood 2001;97:2286-92.
50. Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 1997;17:495-505.
51. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003;102:262-8.
52. Murre C, McCaw PS, Vaessin H, Gaudy M, Jan LY, Jan YN, et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 1989;58:537-44.
53. Hsu HL, Cheng JT, Chen Q, Baer R. Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins. Mol Cell Biol 1991;11:3037-42.
54. Hsu HL, Huang L, Tsan JT, Funk W, Wright WE, Hu JS, et al. Preferred sequences for DNA recognition by the TALI helix-loop-helix proteins. Mol Cell Biol 1994;14:1256-65.
55. Miyamoto A, Cui X, Naumovski L, Cleary ML. Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells. Mol Cell Biol 1996;16:2394-401.
56. Xia Y, Hwang LY, Cobb MH, Baer R. Products of the TAL2 oncogene in leukemic T cells: bHLH phosphoproteins with DNA-binding activity. Oncogene 1994;9:1437-46.
57. Baer R. TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol 1993;4:341-7.
58. Mellentin JD, Smith SD, Cleary ML. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 1989;58:77-83.
59. Visvader J, Begley CG, Adams JM. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene 1991;6:187-94.
60. Carroll AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, et al. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990;76:1220-4.
61. Bernard O, Guglielmi P, Jonveaux P, Cherif D, Gisselbrecht S, Mauchauffe M, et al. Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias. Genes Chromosomes Cancer 1990;1:194-208.
62. Finger LR, Kagan J, Christopher G, Kurtzberg J, Hershfield MS, Nowell PC, et al. Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci USA 1989;86:5039-43.
63. Begley CG, Aplan PD, Denning SM, Haynes BF, Waldmann TA, Kirsch IR. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci USA 1989;86:10128-32.
64. Chen Q, Cheng JT, Tasi LH, Schneider N, Buchanan G, Carroll A, et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J 1990;9:415-24.
65. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 1990;250:1426-9.
66. Bash RO, Hall S, Timmons CF, Crist WM, Amylon M, Smith RG, et al. Does activation of the TALI gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study. Blood 1995;86:666-76.
67. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, Wu C, et al. An sel gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J 1997;16:2408-19.
68. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004;5:587-96.
69. Xia Y, Brown L, Yang CY, Tsan JT, Siciliano MJ, Espinosa R, III, et al. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc Natl Acad Sci USA 1991;88:11416-20.
70. McGuire EA, Hockett RD, Pollock KM, Bartholdi MF, O'Brien SJ, Korsmeyer SJ. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol 1989;9:2124-32.
71. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p15. Proc Natl Acad Sci U S A 1991;88:4367-71.
72. Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991;6:1887-93.
73. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood 2004;104:4173-80.
74. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I, et al. Protein dimerization between Lmo2 (Rbtn2) and Tall alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 1996;15:1021-7.
75. Berger R, Flandrin G, Bernheim A, Le CM, Vecchione D, Pacot A, et al. Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogenet 1987;29:9-21.
76. Berger R, Le CM, Derre J, Vecchione D, Chen SJ. Chromosomal rearrangement on chromosome 11q14-q21 in T cell acute lymphoblastic leukemia. Leukemia 1989;3:560-2.
77. Heim S, Bekassy AN, Garwicz S, Heldrup J, Kristorfersson U, Mandahl N, et al. Bone marrow karyotypes in 94 children with acute leukemia. Eur J Haematol 1990;44:227-33.
78. Sait SN, Dal CP, Sandberg AA. Recurrent involvement of 11q13 in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1987;26:351-4.
79. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci USA 1996;93:4804-9.
80. Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003;102:1000-6.
81. Wechsler DS, Engstrom LD, Alexander BM, Motto DG, Roulston D. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein. Genes Chromosomes Cancer 2003;36:26-36.
82. Chaplin T, Bernard O, Beverloo HB, Saha V, Hagemeijer A, Berger R, et al. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 1995;86:2073-6.
83. Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 2001;13:299-306.
84. Carrera AC, Rodriguez-Borlado L, Martinez-Alonso C, Merida I. T cell receptor-associated a-phosphatidylinositol 3-kinase becomes activated by T cell receptor cross-linking and requires pp56lck. J Biol Chem 1994;269:19435-40.
85. Zipfel PA, Zhang W, Quiroz M, Pendergast AM. Requirement for Abl kinases in T cell receptor signaling. Curr Biol 2004;14:1222-31.
86. Zhang W, Samelson LE. The role of membrane-associated adaptors in T cell receptor signalling. Semin Immunol 2000;12:35-41.
87. Leo A, Wienands J, Baier G, Horejsi V, Schraven B. Adapters in lymphocyte signaling. J Clin Invest 2002;109:301-9.
88. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300:765-7.
89. de Klein A, Hagemeijer A, Bartram CR, Houwen R, Hoefsloot L, Carbonell F, et al. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986;68:1369-75.
90. Quentmeier H, Cools J, Macleod RA, Marynen P, Uphoff CC, Drexler HG. e6-a2 BCR-ABL1 fusion in T-cell acute lymphoblastic leukemia. Leukemia 2005;19:295-6.
91. De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005;105;4849-52.
92. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001;30:274-82.
93. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
94. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000.
95. Tycko B, Smith SD, Sklar J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J Exp Med 1991;174:867-73.
96. Wright DD, Sefton BM, Kamps MP. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol 1994;14:2429-37.
97. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-413.
98. Lubbert M, Mirro J, Jr., Miller CW, Kahan J, Isaac G, Kitchingman G, et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 1990;75:1163-9.
99. Yokota S, Nakao M, Horiike S, Seriu T, Iwai T, Kaneko H, et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol 1998;67:379-87.
100. Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, et al. Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia. Blood 1995;85:2546-52.
101. von Lintig FC, Huvar I, Law P, Diccianni MB, Yu AL, Boss GR. Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin Cancer Res 2000;6:1804-10.
102. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
103. Gibbs JB, Oliff A, Kohl NE. Farnesyl-transferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994;77:175-8.
104. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005;4:77-84.
105. Ward SG, Cantrell DA. Phosphoinositide 3-kinases in T lymphocyte activation. Curr Opin Immunol 2001;13:332-8.
106. Seminario MC, Wange RL. Lipid phosphatases in the regulation or T cell activation: living up to their PTEN-tial. Immunol Rev 2003;192:80-97.
107. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG. Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004;320:932-8
108. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
109. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004;104:558-60.
110. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-12.
111. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT, et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000;95:3891-9.
112. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
113. Huntly BJ, Gilliland DG. Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer Cell 2004;6:199-201.
114. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17:3029-35.
115. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005;6:314-22
116. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61.
117. Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, Macdonald HR, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999;10:547-58.
118. Wolfer A, Wilson A, Nemir M, Macdonald HR, Radtke F. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early ab Lineage Thymocytes. Immunity 2002;16:869-79.
119. Radtke F, Wilson A, Mancini SJ, Macdonald HR. Notch regulation of lymphocyte development and function. Nat Immunol 2004;5:247-53.
120. Rand MD, Grimm LM, Artavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol 2000;20:1825-35.
121. Sanchez-Irizarry C, Carpenter AC, Weng AP, Pear WS, Aster JC, Blacklow SC. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Mol Cell Biol 2004;24:9265-73.
122. Schweisguth F. Notch signaling activity. Curr Biol 2004;14:R129-R138.
123. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
124. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003;40:274-80.
125. Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr Top Med Chem 2005;5:167-79.
126. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005;14:457-77.
127. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
128. Sternberg DW, Licht JD. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Curr Opin Hematol 2005;12:7-13.
129. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-8.